Z-VAD-FMK |
|||
| A1902-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 224 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| 1140-1 | Biovision | EUR 294 | |
Z-VAD-FMK |
|||
| 1140-5 | Biovision | EUR 805 | |
Z-VAD(OMe)-FMK |
|||
| HY-16658 | MedChemExpress | 10mg | EUR 394 |
Z-VAD-FMK, cell permeable |
|||
| GL1523-1MG | Glentham Life Sciences | 1 mg | EUR 275 |
Z-VAD-FMK, cell permeable |
|||
| GL1523-5MG | Glentham Life Sciences | 5 mg | EUR 792 |
Caspase-Family Inhibitor Z-VAD-FMK |
|||
| 1010-100 | Biovision | EUR 196 | |
Caspase-Family Inhibitor Z-VAD-FMK |
|||
| 1010-20C | Biovision | EUR 196 | |
SRB-VAD-FMK [Sulforhodamine B-VAD-FMK] |
|||
| 13472 | AAT Bioquest | 25 Tests | EUR 132 |
Z-VAD-FMK (Pan-specific caspase inhibitor) |
|||
| SIH-557-1MG | Stressmarq | 1 mg | EUR 193 |
|
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml). |
|||
Biotin-VAD-FMK |
|||
| HY-100894 | MedChemExpress | 1mg | EUR 1014 |
TF4-VAD-FMK |
|||
| 13471 | AAT Bioquest | 25 Tests | EUR 132 |
FITC-VAD-FMK |
|||
| 9497-100 | Biovision | EUR 359 | |
Biotin-VAD-FMK |
|||
| 1123-20C | Biovision | EUR 327 | |
mFluor™ 450-VAD-FMK |
|||
| 13475 | AAT Bioquest | 25 Tests | EUR 132 |
mFluor™ 510-VAD-FMK |
|||
| 13476 | AAT Bioquest | 25 Tests | EUR 132 |
Z-IETD-FMK |
|||
| HY-101297 | MedChemExpress | 5mg | EUR 463 |
Z-DEVD-FMK |
|||
| HY-12466 | MedChemExpress | 10mg | EUR 393 |
Z-VRPR-FMK |
|||
| GL3755-1MG | Glentham Life Sciences | 1 mg | EUR 585 |
Z-VRPR-FMK |
|||
| GL3755-500UG | Glentham Life Sciences | 500 ug | EUR 355 |
Z-DEVD-FMK |
|||
| A1920-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 293 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DQMD-FMK |
|||
| A1921-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 432 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-VDVAD-FMK |
|||
| A1922-1 | ApexBio | 1 mg | EUR 177 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-10 | ApexBio | 10 mg | EUR 630 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-25 | ApexBio | 25 mg | EUR 978 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-5 | ApexBio | 5 mg | EUR 398 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VEID-FMK |
|||
| A1923-1 | ApexBio | 1 mg | EUR 177 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-10 | ApexBio | 10 mg | EUR 630 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-25 | ApexBio | 25 mg | EUR 978 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-5 | ApexBio | 5 mg | EUR 398 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-WEHD-FMK |
|||
| A1924-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-WEHD-FMK |
|||
| A1924-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-WEHD-FMK |
|||
| A1924-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-WEHD-FMK |
|||
| A1924-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-IETD-FMK |
|||
| B3232-1 | ApexBio | 1 mg | EUR 328 |
|
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
|||
Z-IETD-FMK |
|||
| B3232-5 | ApexBio | 5 mg | EUR 456 |
|
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
|||
Z-IETD-FMK |
|||
| B3232-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 1001 |
|
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
|||
Z-LEHD-FMK |
|||
| B3233-1 | ApexBio | 1 mg | EUR 350 |
|
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway. |
|||
Z-LEHD-FMK |
|||
| B3233-5 | ApexBio | 5 mg | EUR 879 |
|
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway. |
|||
Z-FA-FMK |
|||
| A8170-1 | ApexBio | 1 mg | EUR 119 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-10 | ApexBio | 10 mg | EUR 467 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-5 | ApexBio | 5 mg | EUR 282 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 340 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-YVAD-FMK |
|||
| A8955-1 | ApexBio | 1 mg | EUR 235 |
|
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
|||
Z-YVAD-FMK |
|||
| A8955-5 | ApexBio | 5 mg | EUR 514 |
|
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
|||
Z-YVAD-FMK |
|||
| A8955-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 1105 |
|
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
|||
Z-AEVD-FMK |
|||
| B1162-1 | Biovision | EUR 338 | |
Z-AEVD-FMK |
|||
| B1162-5 | Biovision | EUR 914 | |
Z-VRPR-FMK |
|||
| B1238-1000 | Biovision | EUR 914 | |
Z-VRPR-FMK |
|||
| B1238-250 | Biovision | EUR 338 | |
Z-YVAD-FMK |
|||
| 1141-1 | Biovision | EUR 338 | |
Z-YVAD-FMK |
|||
| 1141-5 | Biovision | EUR 805 | |
Z-VDVAD-FMK |
|||
| 1142-1 | Biovision | EUR 305 | |
Z-VDVAD-FMK |
|||
| 1142-5 | Biovision | EUR 805 | |
Z-DEVD-FMK |
|||
| 1143-1 | Biovision | EUR 316 | |
Z-DEVD-FMK |
|||
| 1143-5 | Biovision | EUR 805 | |
Z-LEVD-FMK |
|||
| 1144-1 | Biovision | EUR 316 | |